These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16551691)

  • 21. Comparative elution of moxifloxacin from Norian skeletal repair system and acrylic bone cement: an in vitro study.
    Kanellakopoulou K; Tsaganos T; Athanassiou K; Koutoukas P; Raftogiannis M; Skiadas I; Giamarellou H
    Int J Antimicrob Agents; 2006 Sep; 28(3):217-20. PubMed ID: 16904297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
    Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect.
    Kanellakopoulou K; Pagoulatou A; Stroumpoulis K; Vafiadou M; Kranidioti H; Giamarellou H; Giamarellos-Bourboulis EJ
    J Antimicrob Chemother; 2008 Jun; 61(6):1328-31. PubMed ID: 18353805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penetration of moxifloxacin into liver tissue.
    Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
    Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a synthetic carrier of calcium sulphate (Stimulan) releasing moxifloxacin.
    Kanellakopoulou K; Galanopoulos I; Soranoglou V; Tsaganos T; Tziortzioti V; Maris I; Papalois A; Giamarellou H; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2009 Apr; 33(4):354-9. PubMed ID: 19097865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration.
    Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X
    Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.
    Cárceles CM; Escudero E; Fernández-Varón E; Marín P
    Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
    Goudah A; Hasabelnaby S
    Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of moxifloxacin compared to teicoplanin in the treatment of implant-related chronic osteomyelitis in rats.
    Ozturan KE; Yucel I; Kocoglu E; Cakici H; Guven M
    J Orthop Res; 2010 Oct; 28(10):1368-72. PubMed ID: 20839321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
    Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
    Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition kinetics of moxifloxacin in lactating ewes.
    Goudah A
    Vet J; 2008 Nov; 178(2):282-7. PubMed ID: 17900948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftriaxone bone penetration in patients with septic non-union of the tibia.
    Garazzino S; Aprato A; Baietto L; D'Avolio A; Maiello A; De Rosa FG; Aloj D; Siccardi M; Biasibetti A; Massè A; Di Perri G
    Int J Infect Dis; 2011 Jun; 15(6):e415-21. PubMed ID: 21497532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
    Hariprasad SM; Shah GK; Chi J; Prince RA
    J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.
    Tzepi I; Vergados I; Kanellakopoulou K; Papathanassiou M; Kranidioti H; Tsaganos T; Liarakos V; Giamarellos-Bourboulis EJ; Theodossiadis P
    Int J Antimicrob Agents; 2009 Feb; 33(2):160-2. PubMed ID: 18947985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitreal penetration of oral and topical moxifloxacin in humans.
    Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
    Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis.
    Burkhardt O; Derendorf H; Jäger D; Kumar V; Madabushi R; Röhl K; Barth J
    Scand J Infect Dis; 2006; 38(10):904-8. PubMed ID: 17008236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.